Literature DB >> 20502419

Idiopathic venous thrombosis is related to systemic inflammatory response and to increased levels of circulating markers of endothelial dysfunction.

M K Jezovnik1, P Poredos.   

Abstract

AIM: During the past decade, the role of inflammation in the pathophysiology of arterial thrombosis has been elucidated. However, little is known about the relationship between inflammation and venous thrombosis. Recently, inflammation has been accepted as a possible mechanism through which different risk factors trigger thrombus formation in veins. The aim of the present study was to investigate the inflammatory markers and their relationship to idiopathic venous thrombosis.
METHODS: Fourty-nine patients with first idiopathic venous thrombosis and 48 age matched control subjects were included in the study. Patients were studied 2-4 months after the acute event. Patients and control subjects did not differ in the classical risk factors of atherosclerosis, except in body mass index. In both groups, blood markers of inflammation, namely high sensitive C-reactive protein (hs CRP), interleukins (IL-6, IL-8) and tumour necrosis factor alpha (TNF-a), and circulating markers of endothelial dysfunction/damage namely von Willebrand factor (vWF), P-selectin and the vascular adhesion molecule (VCAM-1) were measured.
RESULTS: In comparison to healthy subjects patients had significantly higher levels of inflammatory markers: hs CRP: 2.58 mg/L (1.37-6.61), vs. 1.67 mg/L (0.97-3.24) P=0.044, IL-6: 2.37 pg/mL (1.59-4.10), vs. 2.03 pg/mL (1.45-2.59), P=0.025, IL-8: 3.53 pg/mL (2.94-5.3), vs. 2.25 pg/mL (1.77-2.90) P < or = 0.0001. However, concentrations of TNF-a did not differ significantly between the groups. Also in patients higher levels of circulating markers of endothelial dysfunction: vWF 150.0 g/L (121.0-195.0) vs. 91.5 g/L (70.5-104.0), P < or = 0.0001, P-selectin 39.5 pg/L (34.0-40.6) vs. 34.8 pg/L (32.5-38.6) P=0.009. In contrast, levels of VCAM-1 were comparable between the groups. The levels of some inflammatory markers were related to the concentration of von Willebrand factor and P-selectin - IL-6: vWF (r=0.36, P=0.08), hs CRP: P-selectin (r=0.44, P=0.018), IL-6: P-selectin (r=0.51, P=0.0002), IL-8: P-selectin (r=0.38, P=0.043).
CONCLUSION: Patients with idiopathic venous thrombosis have increased levels of circulating markers of inflammation and blood markers of endothelial dysfunction. Higher levels of both groups of markers indicate that patients in the stable phase of the disease have an increased systemic inflammatory response. The interrelationship between inflammatory markers and markers of endothelial dysfunction favour the hypothesis that inflammation could be involved in the etiopathogenesis of idiopathic venous thrombosis.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20502419

Source DB:  PubMed          Journal:  Int Angiol        ISSN: 0392-9590            Impact factor:   2.789


  22 in total

1.  Less deep vein thrombosis due to transcutaneous fibular nerve stimulation in total knee arthroplasty: a randomized controlled trial.

Authors:  Masashi Izumi; Masahiko Ikeuchi; Koji Aso; Natsuki Sugimura; Yuko Kamimoto; Tetsuya Mitani; Tadashi Ueta; Takayuki Sato; Masataka Yokoyama; Tetsuro Sugiura; Toshikazu Tani
Journal:  Knee Surg Sports Traumatol Arthrosc       Date:  2014-06-24       Impact factor: 4.342

2.  Assessment of Prognostic Value of Neutrophil to Lymphocyte Ratio and Platelet to Lymphocyte Ratio in Patients with Pulmonary Embolism.

Authors:  Mehmet Baran Karataş; Göktürk İpek; Tolga Onuk; Barış Güngör; Gündüz Durmuş; Yiğit Çanga; Yasin Çakıllı; Osman Bolca
Journal:  Acta Cardiol Sin       Date:  2016-05       Impact factor: 2.672

3.  Shear stress-induced unfolding of VWF accelerates oxidation of key methionine residues in the A1A2A3 region.

Authors:  Xiaoyun Fu; Junmei Chen; Ryan Gallagher; Ying Zheng; Dominic W Chung; José A López
Journal:  Blood       Date:  2011-09-13       Impact factor: 22.113

4.  High-sensitivity C-reactive protein is not a risk factor for venous thromboembolism: the Tromso study.

Authors:  Erin M Hald; Sigrid K Brækkan; Ellisiv B Mathiesen; Inger Njølstad; Tom Wilsgaard; Jan Brox; John-Bjarne Hansen
Journal:  Haematologica       Date:  2011-04-20       Impact factor: 9.941

Review 5.  Polymyalgia rheumatica and risk of coronary artery disease: a systematic review and meta-analysis of observational studies.

Authors:  Patompong Ungprasert; Matthew J Koster; Kenneth J Warrington; Eric L Matteson
Journal:  Rheumatol Int       Date:  2016-08-30       Impact factor: 2.631

Review 6.  Risk of venous thromboembolism in patients with idiopathic inflammatory myositis: a systematic review and meta-analysis.

Authors:  Patompong Ungprasert; Anawin Sanguankeo
Journal:  Rheumatol Int       Date:  2014-04-20       Impact factor: 2.631

7.  Plasma MMP and TIMP evaluation in patients with deep venous thrombosis: could they have a predictive role in the development of post-thrombotic syndrome?

Authors:  Stefano de Franciscis; Luca Gallelli; Bruno Amato; Lucia Butrico; Alessio Rossi; Gianluca Buffone; Francesco G Caliò; Giovanni De Caridi; Raffaele Grande; Raffaele Serra
Journal:  Int Wound J       Date:  2015-09-24       Impact factor: 3.315

8.  ApoM Suppresses TNF-α-Induced Expression of ICAM-1 and VCAM-1 Through Inhibiting the Activity of NF-κB.

Authors:  Ji-Juan Gao; Yan-Wei Hu; Yan-Chao Wang; Yan-Hua Sha; Xin Ma; Shu-Fen Li; Jia-Yi Zhao; Jing-Bo Lu; Chuan Huang; Jing-Jing Zhao; Lei Zheng; Qian Wang
Journal:  DNA Cell Biol       Date:  2015-06-09       Impact factor: 3.311

9.  Assessment of inflammatory biomarkers and oxidative stress in pulmonary thromboembolism: follow-up results.

Authors:  Bilal Halici; Sevinc Sarinc Ulasli; Ersin Günay; Serkan Nural; Serkan Sen; Olcay Akar; Sefa Celik; Mehmet Unlu
Journal:  Inflammation       Date:  2014-08       Impact factor: 4.092

10.  Inflammatory plasma markers and risk for venous thromboembolism.

Authors:  Signy V Sveinsdottir; Peter J Svensson; Gunnar Engström
Journal:  J Thromb Thrombolysis       Date:  2014       Impact factor: 2.300

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.